Theragnostics Expands Team with Significant Appointments

LONDON, Jan. 10, 2020 – Theragnostics, which is developing molecular radiotherapy for imaging and treating a broad range of cancers, announces the appointments of Dr. Alex Jackson as Head of Research and Development and of Archie Hale as Director of Clinical Operations. This announcement follows the recent appointment of radiopharmaceutical drug development expert Dr. Daniel Stevens as Chief Medical Officer.

Dr. Jackson has over 20 years’ experience of conducting and overseeing research activities in both academia and industry. He joins Theragnostics from GE Healthcare where he was responsible for the discovery phase of immune-oncology PET projects and for a multi-centre late stage clinical PET tracer development programme. Alex holds a PhD in Synthetic Chemistry from the University of Warwick and he is the author of 15 publications on molecular imaging and radiochemistry.

Read more

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...

GET IN TOUCH